Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

Gantenerumab shows promise in preventing Alzheimers disease after past failures Gantenerumab demonstrates significant ...

A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

A study examining the long-term effects of anti-amyloid therapy gantenerumab suggests that full amyloid plaque removal may help reduce Alzheimer’s symptoms in individuals at risk for dominantly ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.